UCLA Health researchers have identified a potential drug target for treating fragile X syndrome (FXS), the most common genetic cause of intellectual disability and autism that affects roughly one in 2,000 boys. This breakthrough comes from a study led by Dr. Carlos Portera-Cailliau, which highlights the synaptic protein EPAC2 as a promising therapeutic target.
Fragile X syndrome results from a mutation in the FMR1 gene, leading to a loss of the fragile X messenger ribonucleoprotein (FMRP) essential for brain development. The research team utilized genetically engineered mice to demonstrate that blocking EPAC2 restored brain activity and improved behavioral symptoms associated with FXS. This finding is significant as it suggests a new avenue for targeted therapies, especially given the historical challenges in finding effective treatments for this condition.
Given that EPAC2 is primarily expressed in the brain, therapies targeting this protein may minimize off-target effects, enhancing safety in future clinical applications. The study’s results emphasize the need for innovative approaches in developing treatments for FXS, particularly for older children and adults, as EPAC2 levels increase with brain maturation. This research not only advances the understanding of FXS but also sets a precedent for utilizing transcriptomic analyses to identify novel therapeutic targets in neurodevelopmental disorders.
Start your 7-day trial and see what the database can do →
